Lung diseases are now one of the commonest causes of death and disability worldwide and are increasing in incidence.  Fibrotic lung diseases have a particularly poor prognosis.  At present there are no diagnostic markers identified in peripheral blood or tissue samples that are routinely available to predict outcome and permit disease progress to be easily monitored.  This represents a major unmet health need both in Ireland and worldwide

      This project is jointly funded by the Health Research Board and Science Foundation Ireland, and will focus on the development of new diagnostic methods development in these diseases based on our recent identification of the bone morphogenetic antagonist gremlin as an important mediator of chronic hypoxic lung diseases.  The major aim of the project is to translate recent basic research findings from our laboratory into a clinical context so that earlier diagnosis and improved disease monitoring will lead in the longer term to improved management and treatment of fibrotic lung diseases.

中国-博士人才网发布